Tirtha Chakraborty
Technik-/Wissenschafts-/F&E-Leiter bei VOR BIOPHARMA INC.
Vermögen: 241 965 $ am 31.05.2024
Aktive Positionen von Tirtha Chakraborty
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VOR BIOPHARMA INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2020 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Berater | 24.07.2023 | - |
Karriereverlauf von Tirtha Chakraborty
Ehemalige bekannte Positionen von Tirtha Chakraborty
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01.10.2018 | 01.10.2019 |
| CRISPR THERAPEUTICS AG | Direktor/Vorstandsmitglied | 01.01.2015 | 01.10.2018 |
| Corporate Officer/Principal | 01.01.2015 | 01.10.2018 |
Ausbildung von Tirtha Chakraborty
| Tata Institute of Fundamental Research | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Indien | 2 |
| Schweiz | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Börse
- Insiders
- Tirtha Chakraborty
- Erfahrung
